TABLE 4.
Average and minimal concentrations as predicted from the covariate model for tenofovir (TFV), emtricitabine (FTC) and their metabolites (TFV-DP and FTC-TP)
| Concentration | Regimen | Median (range) for: |
|||
|---|---|---|---|---|---|
| TFV (ng/mL) | TFV-DP (fmol/106 cells) | FTC (ng/mL) | FTC-TP (pmol/106 cells) | ||
| C avg | ANRS 134-COPHAR 3a | 99 (37–262) | 136 (31–239) | 413 (111–932) | 8 (2–18) |
| 7 days/wkb | 107 (45–265) | 146 (91–239) | 440 (208–922) | 8 (4–18) | |
| 4 days/wkb | 61 (25–152) | 101 (55–172) | 251 (119–527) | 5 (2–12) | |
| C min | ANRS 134-COPHAR 3a | 28 (0–68) | 125 (0–234) | 54 (0–142) | 6 (0–16) |
| 7 days/wkb | 52 (15–130) | 142 (88–234) | 78 (25–248) | 8 (3–17) | |
| 4 days/wkb | 1 (0–5) | 8 (44–151) | 11 (0–46) | 3 (1–7) | |
a
In the 34 patients of the ANRS 124-COPHAR 3 trial from W4 to the last observation, according to dosing history.
b
In 1,000 subjects over a two-week window at steady state, assuming perfect adherence.